Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Trial end date:
2018-01-02
Target enrollment:
Participant gender:
Summary
Neuropathic pain / peripheral neuropathy (NP/PN) is a known painful complication of
vincristine (VCR) therapy; evidence supporting the best treatment plan for pediatric patients
is limited. Gabapentin is frequently used for VCR-related NP/PN, with variable dosing and
scheduling regimens, and with varying measures of success. The hypothesis of the study is
that gabapentin will reduce the severity of NP/PN in patients receiving vincristine during
treatment for ALL on the Total XVI protocol (or for those being treated "as per TOTXVI
protocol"), as measured by two outcome measures: the daily dose of morphine used as needed
for pain in addition to either gabapentin or placebo, as randomized, and the pain scores
assessed daily.